RV41 Stock Overview
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Fennec Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.45 |
| 52 Week High | US$10.40 |
| 52 Week Low | US$5.95 |
| Beta | 0.40 |
| 1 Month Change | -13.33% |
| 3 Month Change | -7.14% |
| 1 Year Change | 14.97% |
| 3 Year Change | 69.00% |
| 5 Year Change | 127.89% |
| Change since IPO | -89.57% |
Recent News & Updates
Recent updates
Shareholder Returns
| RV41 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 2.4% | 0.8% | -0.5% |
| 1Y | 15.0% | -21.0% | 2.5% |
Return vs Industry: RV41 exceeded the German Biotechs industry which returned -19.8% over the past year.
Return vs Market: RV41 exceeded the German Market which returned 1.8% over the past year.
Price Volatility
| RV41 volatility | |
|---|---|
| RV41 Average Weekly Movement | 6.3% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: RV41 has not had significant price volatility in the past 3 months.
Volatility Over Time: RV41's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 29 | Rosty Raykov | www.fennecpharma.com |
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company in the United States. The company’s product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.
Fennec Pharmaceuticals Inc. Fundamentals Summary
| RV41 fundamental statistics | |
|---|---|
| Market cap | €231.48m |
| Earnings (TTM) | -€14.96m |
| Revenue (TTM) | €19.81m |
11.7x
P/S Ratio-15.5x
P/E RatioIs RV41 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RV41 income statement (TTM) | |
|---|---|
| Revenue | US$21.25m |
| Cost of Revenue | US$1.26m |
| Gross Profit | US$19.99m |
| Other Expenses | US$36.04m |
| Earnings | -US$16.04m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.59 |
| Gross Margin | 94.08% |
| Net Profit Margin | -75.50% |
| Debt/Equity Ratio | -266.1% |
How did RV41 perform over the long term?
See historical performance and comparison